Therapy News and Research

RSS
BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

Hospice and Palliative care

Hospice and Palliative care

CTI, Chroma enter agreement to co-develop and license tosedostat

CTI, Chroma enter agreement to co-develop and license tosedostat

U-M's CoreValve trial to offer less invasive approach for patients with aortic stenosis

U-M's CoreValve trial to offer less invasive approach for patients with aortic stenosis

Tamoxifen against breast cancer can save lives and reduce medical costs

Tamoxifen against breast cancer can save lives and reduce medical costs

Women with DCIS have excellent overall prognosis despite treatment

Women with DCIS have excellent overall prognosis despite treatment

EMP levels may help clinicians diagnose early emphysema

EMP levels may help clinicians diagnose early emphysema

New PTLD Guideline highlighted at NCCN Annual Conference

New PTLD Guideline highlighted at NCCN Annual Conference

HIV infection and increased fracture risk: Study

HIV infection and increased fracture risk: Study

Combination therapy may overcome Herceptin-resistant breast cancer

Combination therapy may overcome Herceptin-resistant breast cancer

Alzheimer's vaccine - First evidence for efficacy

Alzheimer's vaccine - First evidence for efficacy

New drug for Lupus approved

New drug for Lupus approved

Acupuncture for menopausal hot flashes: Study

Acupuncture for menopausal hot flashes: Study

Updated NCCN Guidelines for Breast Cancer outline expanded treatment options

Updated NCCN Guidelines for Breast Cancer outline expanded treatment options

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Centric Health 2010 revenue increases 70% to $62.5 million

Centric Health 2010 revenue increases 70% to $62.5 million

Majority of men on ADT after prostatectomy gain weight during first year of therapy

Majority of men on ADT after prostatectomy gain weight during first year of therapy

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

Simcere files IND with SFDA of China for APX003 to treat cancer

Simcere files IND with SFDA of China for APX003 to treat cancer

Erlotinib, Gefitinib effective in treating certain subset of advanced NSCLC patients

Erlotinib, Gefitinib effective in treating certain subset of advanced NSCLC patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.